GlassScriptPhysician profile
Munaf A Shamji
NPI 1174587224
$5,709.66
in general payments reported to CMS, 2019-2025
33 companies · $719 in 2025
The $719 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $501 · 2021: $534 · 2022: $666 · 2023: $1,210 · 2024: $857 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,785.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $872.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $628.56 | 2019-2025 | |
| Edwards Lifesciences Corporation | $470.97 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $406.10 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $325.85 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $298.10 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $282.40 | 2019-2025 | Farxiga, Wainua |
| Abbott Laboratories | $279.24 | 2019-2021 | |
| Amgen INC. | $229.28 | 2019-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $159.67 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.65 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.00 | 2020-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $133.23 | 2021-2025 | Amvuttra, Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $131.54 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $123.59 | 2021-2023 | Arcalyst |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $104.97 | 2019-2021 | |
| Novo Nordisk INC | $94.68 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $93.42 | 2021-2023 | Mycarelink, Azure Xt Dr Mri Surescan |
| Baxter Healthcare | $93.14 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $88.47 | 2023-2024 | Inpefa |
| Ge Healthcare | $79.14 | 2024 | |
| Sanofi-Aventis U.S. LLC | $78.76 | 2019-2024 | |
| Pulmonx Corporation | $75.51 | 2020 | |
| Biotronik INC. | $59.13 | 2019-2021 | |
| Nevro Corp. | $58.05 | 2022 | |
| Heartflow, INC. | $49.55 | 2022-2025 | |
| Cvrx, INC. | $47.01 | 2023-2024 | Barostim Neo System |
| Boston Scientific Corporation | $34.94 | 2023-2024 | Accolade Sr, Bodyguardian |
| Actelion Pharmaceuticals US, INC. | $31.72 | 2020-2023 | Opsumit, Uptravi |
| G Medical Diagnostic Services, INC. | $25.16 | 2021-2022 | |
| Philips North America LLC | $17.43 | 2022 | |
| Scpharmaceuticals INC. | $15.91 | 2023 | |
| Gilead Sciences, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munaf Shamji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.